WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.

• Autores principales: Afif Ben Salah (Autor), Pierre A Buffet (Autor), Gloria Morizot (Autor), Nathalie Ben Massoud (Autor), Amor Zâatour (Autor), Nissaf Ben Alaya (Autor), Nabil Bel Haj Hamida (Autor), Zaher El Ahmadi (Autor), Matthew T Downs (Autor), Philip L Smith (Autor), Koussay Dellagi (Autor), Max Grögl (Autor)
• Formato: Libro
• Publicado: Public Library of Science (PLoS), 2009-01-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Cutaneous leishmaniasis (cl) is a disfiguring disease that confronts clinicians with a quandary: leave patients untreated or engage in a complex or toxic treatment. Topical treatment of CL offers a practical and safe option. Accordingly, the treatment of CL with WR279,396, a formulation of paromomyc...